ESMO GI 2022 Highlights

CME

Key Studies in Gastrointestinal Cancers: Independent Conference Coverage of the ESMO World Congress on Gastrointestinal Cancer 2022

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: October 04, 2022

Expiration: October 03, 2023

Joleen Hubbard
Joleen Hubbard, MD
Rachna Shroff
Rachna Shroff, MD, MS

Activity

Progress
1
Course Completed

At the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022 held in Barcelona, Spain, new clinical trial data were reported for biliary tract cancer (BTC), cholangiocarcinoma, colon cancer, hepatocellular carcinoma (HCC), and esophageal cancer. In this module, Joleen Hubbard, MD, and Rachna T. Shroff, MD, MS, review and discuss the implications of key studies presented at the meeting.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

 

If you are a practicing healthcare professional (HCP), how many patients with gastrointestinal (GI) cancers do you provide care for in a typical month?

Based on findings from the MOUNTAINEER trial of tucatinib combined with trastuzumab, which of the following patient populations with progressive HER2-positive metastatic colorectal cancer (CRC) would you consider as potential candidates for this regimen if it is approved?

Which of the following findings was reported from the RATIONALE-306 phase III trial of tislelizumab or placebo with investigator-chosen chemotherapy (CT) for patients with unresectable locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)?

Based on the extended 5-year follow-up results from the CheckMate 040 phase I/II trial of nivolumab and ipilimumab as subsequent therapy in patients with advanced hepatocellular carcinoma with progression or intolerance with sorafenib, which of the following dose and schedule regimens of nivolumab and ipilimumab is most appropriate to optimize outcomes for these patients?